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Background: IL-6 triggers oncogenic/angiogenic signals and the cytokine-dependent pro-cachexia cascade. The
prognostic role of the functional IL-6 (promoter) rs1800795 and the IL-6R (receptor) rs8192284 single nucleotide
polymorphisms (SNP) was studied in patients with advanced gastric cancer treated with palliative chemotherapy.
Methods: One-hundred-sixty-one patients were genotyped for rs1800795 and rs8192284 SNPs using polymerase
chain reaction based restriction fragment length polymorphism (PCR-RFLP) analysis assay. These results were
studied for association with overall survival (OS).
Results: In 161 assessable patients, frequencies of rs1800795 G/G, G/C and C/C genotypes were 46%, 42% and 12%,
respectively. Frequencies of rs8192284 A/A, A/C and C/C genotypes were 36%, 45% and 19%, respectively. Carriers
of the rs1800795 G/G and rs8192284 C/C genotypes showed the worst OS. In the multivariate model, rs1800795
G/G (1.69 hazard ratio; 95% confidence interval 1.18-2.42), and rs8192284 C/C (1.78 hazard ratio; 95% confidence
interval 1.12-2.83) confirmed an adverse prognostic impact.
Conclusions: In this population, genetic variants that up-regulate the IL-6 system showed impact on OS. This findings
sustain the hypothesis that anti-IL-6 compounds deserve clinical studies as novel therapeutics in the palliative
treatment of cancer patients.
Keywords: Interleukin 6, Gastric cancer, Survival, Prognosis, Chemotherapy, PolymorphismBackground
Interleukin-6 (IL-6) is a four-helical protein of 184 amino
acids that belongs to a large family of pleiotropic cytokine
involved in numerous functions [1]. On target cells, IL-6
binds to an 80 kDa IL-6 receptor (IL-6R). The complex of
IL-6 and IL-6R couples with gp130 protein and triggers
intracellular signaling. Whereas gp130 is expressed on
all cells, IL-6R is only present on few cells in the body
including hepatocytes and some leukocytes [1]. Cells
not expressing IL-6R cannot respond to the cytokine,
since gp130 alone has no measurable affinity for IL-6. A
soluble form of IL-6R (sIL-6R) comprising the extra-
cellular portion of the receptor can bind IL-6 with a
similar affinity as the membrane bound IL-6R. The* Correspondence: annamaria.ruzzo@uniurb.it
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unless otherwise stated.complex of IL-6 and sIL-6R can bind to gp130 on cells,
which do not express the IL-6R, and which are unre-
sponsive to IL-6 [1]. This alternative stimulation has
been called trans-signaling [2]. There is evidence that IL-6
trans-signaling possess a prevalent pro-inflammatory role,
whereas classic IL-6 signaling via the membrane bound
IL-6R is needed for regenerative or anti-inflammatory
processes [2].
Dysregulation of the IL-6/IL-6R system has been associ-
ated with the pathogenesis of several autoimmune and in-
flammatory diseases in humans, and anti-IL-6 monoclonal
antibodies (moAbs) have been successfully developed for
the medical treatment of chronic inflammatory diseases,
like rheumatoid arthritis [3]. Recently, anti-IL-6 moAbs
have drawn attention for their potential effects in can-
cer patients [4,5]. On one side, IL-6 and other pro-
inflammatory cytokines are involved in the mechanismstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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that IL-6 directly induces tumor growth and spread after
triggering the canonical JAK/STAT pathway, an SHP-2
driven Ras-Raf-MAPK signaling pathway and angiogenesis
[4,5]. Activation of these pathways has been documented
in gastric cancer in experimental models and in vivo [7-16].
There is compelling evidence that circulating IL-6 levels
and the levels of its trans-signaling promoting receptor
(sIL-6R) are genetically-driven [17]. The single nucleo-
tide polymorphism (SNP) rs1800795 corresponding to
-174G/C SNP in the IL-6 gene promoter showed higher
transcriptional activity in gene reporter assays [18]. In
vivo, higher IL-6 levels were determined in carriers of
the common allele in studies including both healthy
subjects and patients with inflammatory diseases [18]. A
common non-synonymous variant in IL-6R (rs8192284
A-C, also rs2228145) causes an Asp358Ala amino acid
substitution within the extracellular cleavage domain of
the IL-6R causing proteolytic cleavage of the membrane-
bound IL-6R [19]. In in vivo studies, 358Ala carriers
showed higher concentrations of the so-called soluble
IL-6 receptor (sIL-6R), which is responsible of trans-
signaling [19].
In several reports, an up-regulated IL-6/IL6R system has
shown a prognostic impact in patients with hematologic
malignancies and with solid tumors [20]. This background
and the availability of novel IL-6 targeting moAbs [5]
prompted us to investigate the possible influence of
rs1800795 and rs8192284 on survival of patients with
advanced gastric cancer. This information, beyond ad-
dressing a novel prognostic factor, may be relevant for
the planning of clinical trials with anti-IL-6 therapies in
this lethal disease.
Methods
The study population consisted of consecutive patients
with locally advanced, relapsed of metastatic gastric cancer
who were treated with palliative chemotherapy at three
participating Institution in Central Italy. One-hundred-
seventy-five patients were homogeneously treated with
both first-line and second-line palliative chemotherapy be-
tween 1998 and 2006 [21]. In 161 of 175 patients (92%)
germline DNA was available from stored blood samples or
obtained after DNA extraction from normal mucosa from
archival paraffin-embedded tissues. Data on chemother-
apy, treatment outcomes, baseline characteristics with
routine blood chemistries, and follow-up were fully avail-
able for the 161 assessed patients. The study approval by
the main hospital research and ethics committee (Azienda
Ospedaliera “Ospedali Riuniti Marche Nord”, Pesaro) was
granted by those of affiliate Institutions (University of
Urbino and Campus Biomedico, Rome). Patients gave
their general consent for the storage of their tissues
and subsenquent use for research purposes.Genetic analyses
Patients’ characteristics and their outcomes were unknown
to investigators performing genetic analyses. Genomic
DNA extraction using the QiaAmp kit (Qiagen, Valencia,
CA, USA). A polymerase chain reaction (PCR)–restriction
fragment length polymorphism (RFLP) technique was
used for determining the IL-6R rs8192284 A/C and the
IL-6 rs1800795 G/C genotypes. Genome DNA (10 ng)
was used as a template and PCR was carried out using
the Diatheva 2×PCR Master Mix (Diatheva, Fano, Italy)
with the following conditions: 95°C 10 min ; 95°C 15
sec, 60°C 30 sec, 72°C 30 sec (35 cycles). The two PCR
were performed using the following primer sets: rs1800795,
forward 5’-TTCCCCCTAGTTGTGTCTTGC-3’ and re-
verse 5’-TGGGGCTGATTGGAAACCT-3’; rs8192284 for-
ward 5’-CCTCTTCCTCCTCTATCTTCAATTTT-3’ and
reverse 5’-AATGTGGGCAGTGGTACTGAA-3’. Primer
pairs were designed using the PRIMER3 program
(primer3plus.com). The PCR products were run on a
2% agarose gel after digestion with Nla-III (IL-6,
rs1800795 G/C) or Hind-III (IL-6R, rs8192284 A/C)
restriction enzymes. The predicted band sizes for the
rs1800795 G/C genotypes after Nla-III digestion
were G/G = 75 bp; G/C = 75 bp plus 50/25 bp; C/C =
50/25 bp; the predicted band sizes for the rs8192284
A/C genotypes after Hind-III digestion were A/A =
73; A/C = 73 bp plus 43/30 bp; C/C = 43/30 bp. Sam-
ples with ambiguous results were analyzed by direct se-
quencing using ABI PRISM 310 Genetic Analyzer
(Applied Biosystems, Foster City CA).
Statistical plan
The primary endpoint of the study was the association
between genotypes and overall survival (OS), as calcu-
lated from the start of first-line palliative chemotherapy
until death. Genotypes were checked for deviation from
the Hardy-Weinberg equilibrium using the Pearson X2
test. The X2 test and the Fisher's exact test were used to
test associations between genotypes and categorical vari-
ables describing the clinico-pathologic features of the
study population. Survival curves were plotted using the
Kaplan-Meier and compared using the log-rank test. The
Cox proportional hazards model was used for multivariate
analysis to estimate and test demographic characteristics,
clinical and genetic features for their associations with OS.
In this exploratory study, no formal correction for mul-
tiple comparisons was adopted. However, all the following
variables were included in multivariate Cox model: age,
sex, ECOG performance status, weight loss (>5% in the
four weeks before starting chemotherapy), anemia, albu-
min level, CEA level, tumor grading, histologic subtype
according to Lauren’s classification, tumor location, liver
involvement, presence of peritoneal carcinomatosis,
number of metastatic sites and response to first-line
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an unfavorable genotype, 157 events would allow to
detect an Hazard Ratio (HR) of 1.75 associated with
this group (80% power and 5% type I error for a two-
tailed test). All results were considered significant at
two-sided p < .05 value. All analyses were performed by
using the MedCalc software version 11.1 (MedCalc
Software, Ostend, Belgium).
Results
Characteristics of patients and genotyping
One-hundred-sixty-one patients were analyzed. All of
them received first and second-line chemotherapy and
died after gastric cancer progression. First-line chemother-
apy was oxaliplatin or cisplatin plus a fluoropyrimidne in
150 patients, or bolus/infusional 5-Fluorouracil in 11
patients. Second-line chemotherapy was 5-Fluorouracil
coupled with cisplatin or oxaliplatin in 48 patients, with
CPT-11 in 45 patients, with anthracycline in 33 patients,
with paclitaxel or docetaxel in 25 patients, with VP-16 in
10 patients. Median survival time in the whole group was
9.4 months (range 0.4-34 months).
Carriers of the rs1800795 G/G, G/C and C/C geno-
types were 74 (46%), 68 (42%) and 19 (12%), respectively.
Carriers of the rs8192284 A/A, A/C and C/C genotypes
were 58 (36%), 73 (45%) and 30 (19%), respectively. These
frequencies did not show deviation from Hardy-Weinberg
equilibrium and they are comparable with frequencies
commonly observed in Caucasian populations.
Details of the characteristics of enrolled patients to-
gether with their distribution according to rs1800795 and
rs8192284 genotypes are shown in Table 1. No significant
association was observed except for liver involvement and
rs8192284 genotypes. In particular, rs8192284 C/C car-
riers were prevalent in patients with liver metastases,
while rs8192284 A/A carriers were prevalent in patients
without liver metastases (Table 1).
Survival analyses
Survival curves of carriers of the rs1800795 and rs8192284
genotypes are shown in Figure 1. In carriers of the rs1800795
G/G, G/C and C/C genotypes, median survival times were
8.4, 11 and 12.6 months, respectively (p = 0.01). In carriers
of the rs8192284 A/A, A/C and C/C genotypes median
survival times were 11.7, 10.1 and 8.6 months, respectively
(p = 0.01).
The recessive model was adopted in the multivariate
analysis with rs1800795 G/G and rs8192284 C/C defined
as the risk genotypes. As shown in Table 2, harboring
rs1800795 G/G (1.69 hazard ratio with 95% confidence
interval 1.18-2.42), or rs8192284 C/C (1.78 hazard ratio
with 95% confidence interval 1.12-2.83) confirmed an
adverse impact on OS. Unfavorable survival outcomes
were also significantly associated with poor performancestatus, lack of tumor response to first-line chemother-
apy, >2 metastatic sites and the presence of peritoneal
carcinomatosis.
An additional explorative survival analysis was ad-
dressed to the distribution of the rs1800795 G and
rs8192284 C risk alleles. There were 16 patients (10%)
who were carriers of both unfavorable rs1800795 G/G
and rs8192284 C/C genotypes (4 risk alleles group).
Eight patients (5%) with rs1800795 C/C and rs8192284
A/A genotypes were classified without risk alleles (0 risk
allele group). Twenty-nine (18%), 68 (42%) and 40 (25%)
patients were grouped as carriers of 1 risk allele, 2 risk
alleles, or 3 risk alleles. As shown in Figure 2, patients
with 4 risk alleles showed the worst OS.
Discussion
Clinical studies have demonstrated that increased serum
IL-6 concentrations are associated with advanced tumor
stages and short survival in patients with solid neoplasms
[20]. IL-6 is a potent pleyotropic cytokine that may en-
hance a pro-inflammatory status and promote mecha-
nisms leading to cancer cachexia in the host [1]. Also,
IL-6 directly induces tumor growth and spread after
triggering the canonical JAK/STAT pathway, as well as
the SHP-2 driven Ras-Raf-MAPK signaling pathway and
tumor angiogenesis [2-5]. Because of the restricted ex-
pression of the membrane-bound IL-6 receptor, lym-
phocytes and hepatocytes are the main IL-6 target cells.
This pattern of receptor expression should limit the
amount of cells that can respond to IL-6. However, the
expression of the membrane-bound IL-6R may increase
in cancer cells and alternative mechanisms may induce
detrimental activation of the IL-6 system [22]. In fact,
shedding of the membrane bound form into the local
microenvironment, with production of the soluble form
of the IL-6 receptor (sIL-6R) triggers trans-signalling,
which in turn greatly increases the range of cells that
can respond to IL-6 [22]. Some data indicate that sIL-6R
may also act as an “orphan” molecule without complexing
with IL-6 and gp130 [2]. However, the main effects of the
sIL-6R seem to be agonistic with activation of trans-
signaling in the presence of IL-6 [23].
There is evidence that the level of activity of IL-6 and
its receptor are regulated by functional polymorphisms
in the corresponding genes [17]. The common allele of
a SNP in IL-6 promoter (rs1800795 G > C) enhances
serum concentrations of IL-6 [18], while the minor al-
lele in IL6R (rs8192284 A > C) is a strong inducer of the
soluble form of the IL-6 receptor (sIL-6R) [19]. The
minor IL6R allele also causes an increase in IL-6 circu-
lating levels, but it seems an indirect effect resulting
from reduced IL-6 clearance through membrane-bound
IL-6R [19]. Carriers of genetic variants that up-regulate
IL-6 and sIL-6R secretion may represent sub-groups of
Table 1 Characteristics of the 161 patients and distribution according to genotypes
Patients rs1800795 rs8192284
no. (%) C/C C/G G/G A/A A/C C/C
No (%) p No (%) p
Gender 0.4 0.8
Male 109 (68) 15 (14) 47 (43) 47 (43) 38 (35) 50 (46) 21 (13)
Female 52 (32) 4 (8) 21 (40) 27 (52) 20 (39) 23 (44) 9 (17)
Age (years) 0.06 0.1
> 75 43 (27) 9 (22) 17 (39) 17 (39) 20 (47) 14 (33) 9 (20)
< 75 118 (73) 10 (8) 51 (43) 57 (48) 38 (32) 59 (50) 21 (18)
ECOG PS 0.1 0.7
0 88 (55) 10 (11) 43 (49) 35 (40) 31.(35) 42 (48) 15 (17)
1 73 (45) 9 (12) 25 (34) 39 (54) 27 (37) 31 (43) 15 (20)
Weight loss 0.8 0.3
< 5% 106.(66) 13 (12) 46 (44) 47 (44) 37 (35) 52 (49) 17 (16)
> 5% 55 (34) 6 (11) 22 (40) 27 (49) 21 (38) 21 (38) 13 (24)
Anemia 0.05 0.3
Hb ≥10 gr/dl 113 (70) 11 (10) 43 (38) 59 (52) 43 (38) 52 (43) 18 (16)
Hb < 10 gr/dl 48 (30) 8 (17) 25 (52) 15(31) 15 (31) 21 (44) 12 (25)
Albumin 0.5 0.2
> 3.5 gr/dl 89 (55) 11 (3) 34 (38) 44 (49) 30 (34) 41 (36) 18 (20)
≤ 3.5gr/dl 72 (45) 8 (11) 34 (47) 30 (42) 28 (39) 32 (45) 12 (16)
CEA 0.5 0.4
< 5 ng/ml 96 (60) 10 (10) 44 (46) 42 (44) 36 (38) 45 (47) 15 (15)
≥ 5 ng/ml 65 (40) 9 (14) 24 (37) 32 (49) 22 (34) 28 (43) 15 (23)
Tumor grade 0.1 0.07
G 1-2 78 (49) 10 (12) 27 (35) 41 (53) 29 (37) 30 (38) 19 (25)
G 3 83 (51) 9 (11) 41 (49) 33 (40) 29 (35) 43 (52) 11 (13)
Histotype 0.9 0.1
Intestinal 95 (59) 12 (13) 40 (42) 43 (45) 31 (33) 42 (44) 22 (23)
Diffuse 66 (41) 7 (11) 28 (42) 31 (47) 27 (41) 31 (47) 8 (12)
First line RR 0.07 0.1
CR + PR 76 (47) 10 (13) 25 (33) 41 (54) 27 (36) 39 (51) 10 (13)
SD + PD 85 (53) 9 (10) 43 (51) 33 (39) 31 (36) 34 (40) 20 (24)
Liver mets 0.3 0.002
Absent 98 (60) 9 (9) 44 (45) 45 (46) 40 (41) 48 (49) 10 (10)
Present 63 (40) 10 (16) 24 (38) 29 (46) 18 (29) 25 (40) 20 (31)
LA/LR 0.7 0.6
Yes 90 (56) 10 (11) 36 (40) 44 (49) 35 (39) 40 (45) 15 (16)
No 71 (44) 9 (13) 32 (45) 30 (42) 23 (32) 33 (36) 15 (22)
Peritoneal mets 0.1 0.9
Absent 84 (52) 13 (15) 35 (42) 36 (43) 30 (36) 38 (45) 16 (19)
Present 77 (48) 6 (8) 33 (43) 38 (49) 28 (36) 35 (46) 14 (18)
Metastatic sites 0.6 0.4
1-2 112 (69) 12 (10) 50 (45) 50 (45) 44 (39) 48 (43) 20 (18)
> 2 49 (31) 7 (14) 18 (37) 24 (49) 14 (29) 25 (51) 10 (20)
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Figure 1 Survival analysis with distribution of patients according to rs1800795 genotypes (Panel A) and rs8192284 genotypes
(Panel B).
Ruzzo et al. BMC Cancer 2014, 14:357 Page 5 of 8
http://www.biomedcentral.com/1471-2407/14/357patients with a host-related feature that favors tumor
growth, metastatic spread and cancer cachexia. Notably,
we found that the common G allele of the IL-6 pro-
moter variant (rs1800795) showed association with poor sur-
vival of patients with advanced gastric cancer treated with
palliative chemotherapy. The minor IL-6R C allele (rs8192284)
showed a weaker prognostic role than the IL-6 promoter
variant. However, in support of a “dynamic” modulation of
the IL-6/sIL-6R system, we observed a possible additive ef-
fect with worst survival outcomes in the presence of both
IL-6 and IL-6R unfavorable genotypes (Figure 2).
The different distribution of patients with and without
liver metastasis according to the sIL-6R genotypes would
also support the role of the IL-6/IL-6R system in the ac-
quisition of a specific pattern of metastatic spread [24].
In experimental and in vivo models, IL-6 increases the
metastatic potential of circulating tumor cells and mod-
ulates tissue homeostasis in a target organ of metastasis
such as the liver [25]. Also, sIL-6R-mediated trans-
signaling displays pro-invasive and pro-metastatic signals
[1,2]. It is maximized in rs8192284 IL-6R minor allelecarriers and it is likely to promote hematogenous spread,
causing a specific pattern of metastatic disease [26].
The common G allele of the rs1800795 IL-6 promoter
variant showed association with unfavorable survival out-
comes of patients with ovarian cancer [27], breast cancer
[28,29], neuroblastoma [30] and hematologic malignancies
[31]. To the best of our knowledge, there is only one pub-
lished study reporting the results of a prognostic analysis
of IL-6 polymorphisms in gastric cancer patients [32]. Liao
et al [32] showed a significant association between high
IL-6 circulating levels and poor survival of stage II-III, sur-
gically resected patients, but the rs1800796 IL-6 variant
did not show prognostic role. Notably, they could not in-
vestigate the IL-6 rs1800795 because of the rarity of the
variant allele in Asiatic populations [32], while the func-
tional effects of the IL-6 rs1800796 are less extensively
studied compared with the IL-6 rs1800795.
Less information is available on the clinical impact of
the rs8192284 IL-6R genetic variant. In multiple myeloma
patients the minor rs8192284 C allele showed association
with lower overall survival [33], but in neuroblastoma
Table 2 Results of the multivariate cox proportional
hazards model
Overall survival
HR (95% CI) p value
Gender
Male v. female 0.99 (0.68-1.43) 0.9
Age (years)
≥ 75 v. < 75 1.11 (0.75-1.63) 0.6
ECOG PS
1 vs. 2 2.04 (1.38-3.01) 0.0003
Weight loss
≥5% vs. <5% 1.01 (0.59-1.35) 0.6
Anemia
Hb <10 gr/dl vs. ≥10gr/dl 1.10 (0.75-1.62) 06
Albumin
≤3.5 vs. >3.5 gr/dl 1.01 (0.71-1.45) 0.9
CEA level
≥ 5 ng/ml vs. < 5 ng/ml 1.33 (0.91-1-94) 0.1
Tumor grading
G3 vs. G1-2 0.93 (0.67-1.28) 0.6
Histotype
Diffuse vs. intestinal 1.03 (0.69-1.52) 0.8
First line response rate
PD + SD vs. CR + PR 1.76 (1.21-2.54) 0.002
Liver metastasis
Present vs. absent 1.33 (0.89-1.98) 0.1
LA/LR
Yes vs. no 0.75 (0.51-1.09) 0.1
Peritoneal metastasis
Present vs. absent 1.50 (1.02-2.21) 0.03
Number of metastatic sites
>2 vs. 1-2 1.90 (1.22-2.96) 0.004
rs1800795 genotypes
G/G vs. other 1.69 (1.88-2.42) 0.003
rs8192284 genotypes
C/C vs. other 1.78 (1.12-2.83) 0.01


























Figure 2 Exploratory survival analysis with classification of
patients in five groups according to the number of risk alleles
as defined after the primary survival analysis.
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to the physiology of trans-signaling and recent data on
agonistic and antagonistic properties of sIL-6R [34], it is
likely that sIL-6R and IL-6R genetic variants may display
variable clinical effects depending on tumor type, tumor
stage, concomitant treatments, host related features in-
volving the immune system and the fine tuning of other
cytokines.
Clinical data on the activation of the IL-6/IL-6R sys-
tem should be considered beyond the possible prognos-
tic role. In fact, the effects of IL-6/IL-6R may contributeto explain different sensitivity and clinical outcomes of
patients treated with novel target therapies. At the same
time, IL-6/IL-6R analyses could offer the opportunity of
developing an alternative therapeutic strategy. In pa-
tients with metastatic renal cell cancer, high IL-6 serum
levels were predictive of improved progression-free sur-
vival from the multi-kinase inhibitor Pazopanib com-
pared with placebo [35]. In experimental models, IL-6
showed induction of cancer stem cells and epithelial-
mesenchimal transition phenotype, which are possible
condition for resistance to the anti-HER-2 compounds
trastuzumab and lapatinib [36,37]. High IL-6 levels showed
association with toxicity from Vorinostat in prostate
cancer patients [38]. Anti-IL-6 molecules may counter-
act this, and other detrimental effects enhanced by the
up-regulation of the IL-6 system. Tocilizumab, Siruku-
mab and Siltuximab are three MoAbs currently under
investigations in clinical trials in cancer patients [5].
Ando et al [39] and Hirata et al [40] in recently pub-
lished case reports, described the favorable effects on
cancer cachexia and disease-related symptoms of Toclizu-
mab in an heavily pre-treated cancer patients. Preliminary
data from Phase I-II studies of anti-IL-6 in patients with
multiple myeloma, castration-resistant prostate cancer
and other solid tumors indicate the possible development
of anti-IL-6 in cancer patients [41-43].
Conclusion
Limitations of this study are its retrospective nature and
the lack of a concomitant analysis of the cytokines circu-
lating levels. Therefore, additional studies are needed for
confirming the prognostic role of IL-6 analyses, and for cor-
roborating the hypothesis that subjects with elevated base-
line IL-6 levels and/or an IL-6 enhancing genetic profile
may represent the target population for evaluating the
effects of the anti-IL-6 MoAbs in cancer patients.
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